home / stock / agnpf / agnpf news

AGNPF News and Press, Algernon Pharmaceuticals Inc - Class A From 03/27/24

Stock Information
Company Name: Algernon Pharmaceuticals Inc - Class A
Stock Symbol: AGNPF
Market: OTC
Website: algernonpharmaceuticals.com
Menu
AGNPF AGNPF Quote AGNPF Short AGNPF News AGNPF Articles AGNPF Message Board
Get AGNPF Alerts

News, Short Squeeze, Breakout and More Instantly...
AGNPF - Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it ha...
AGNPF - Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has ...

AGNPF - Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis

VANCOUVER, British Columbia, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company is pleased to announce that it has r...

AGNPF - Algernon Pharmaceuticals increases size of private placement

2023-12-27 07:50:16 ET More on Algernon Pharmaceuticals Algernon Pharmaceuticals announces private placement Seyltx acquires Algernon's chronic cough research program for $2M and 20% stake Financial information for Algernon Pharmaceuticals For further details...
AGNPF - Algernon Pharmaceuticals Announces Increase to Private Placement

VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical development company announces an increase to...

AGNPF - Algernon Pharmaceuticals announces private placement

2023-12-13 02:57:04 ET More on Algernon Pharmaceuticals Seyltx acquires Algernon's chronic cough research program for $2M and 20% stake Financial information for Algernon Pharmaceuticals For further details see: Algernon Pharmaceuticals announces private placement

AGNPF - Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has recei...
AGNPF - Seyltx acquires Algernon's Chronic Cough Research Program for $2M and 20% stake

2023-11-22 07:35:34 ET More on Algernon Pharmaceuticals Financial information for Algernon Pharmaceuticals For further details see: Seyltx acquires Algernon's Chronic Cough Research Program for $2M and 20% stake

AGNPF - Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has...

AGNPF - Algernon gets Japanese patent notice of allowance for treatment of NASH with Repirinast

2023-11-08 07:18:52 ET More on Algernon Pharmaceuticals Financial information for Algernon Pharmaceuticals For further details see: Algernon gets Japanese patent notice of allowance for treatment of NASH with Repirinast
Previous 10 Next 10